(LIVN) LivaNova - Ratings and Ratios

LivaNova PLC (NASDAQ:LIVN) is a global medical device company specializing in innovative therapeutic solutions. The company operates through three distinct segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support.

The Cardiopulmonary segment focuses on life-critical systems used in cardiac surgery. Products include oxygenators, which transfer oxygen to blood during bypass surgery, heart-lung machines that temporarily take over cardiac and respiratory functions, and autotransfusion systems that conserve blood during surgery. These devices are essential for maintaining patient stability during complex procedures.

The Neuromodulation segment is centered around the VNS Therapy System, an FDA-approved implantable device that treats drug-resistant epilepsy and difficult-to-treat depression. This system uses vagus nerve stimulation to modulate brain activity, offering a unique solution for patients who have limited treatment options.

The Advanced Circulatory Support segment develops temporary life support systems, such as extracorporeal membrane oxygenation (ECMO) devices. These systems are used to support patients with severe cardiac or respiratory failure, providing a bridge to recovery or further treatment.

LivaNova serves a diverse range of medical professionals, including perfusionists, neurologists, and cardiothoracic surgeons, as well as hospitals and healthcare providers worldwide. The company’s distribution network includes both direct sales teams and independent distributors, ensuring broad market reach.

Headquartered in London, LivaNova was formed in 2015 through the merger of Sorin S.p.A. and Cyberonics, Inc. The company has established itself as a leader in niche areas of medical technology, with a strong focus on innovation and patient outcomes. For more information, visit their website at https://www.livanova.com.

From a financial perspective, LivaNova PLC (NASDAQ:LIVN) has a market capitalization of approximately $2.75 billion. The stock currently trades with a trailing P/E ratio of 117.77 and a forward P/E of 21.19, reflecting expectations of future earnings growth. The price-to-book ratio stands at 2.10, and the price-to-sales ratio is 2.21, providing investors with key valuation metrics to assess the company’s position in the health care equipment industry.